Alternatively, previously optimised immunohistochemistry for FRMD6 on FFPE material [14] can function as a clinically relevant approach to identify similar patients presenting with poor prognosis mesenchymal CRC that could benefit from treatment with an inhibitor targeting all AKT family members. The gene discussed is FRMD6; the disease is colorectal carcinoma.